Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
暂无分享,去创建一个
A. Naccarati | A. Sapino | S. Bellomo | S. Guarrera | R. Ponzone | F. Montemurro | S. Giordano | Matteo Cereda | N. Crosetto | I. Sarotto | C. Marchiò | L. Annaratone | G. Ferrero | L. Casorzo | E. Berrino | C. Parlato | M. Panero | A. Bragoni | Amedeo Gagliardi | Dora Grassini | A. Gagliardi | M. Cereda | Alberto Bragoni
[1] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.
[2] A. Sapino,et al. Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors , 2022, npj Precision Oncology.
[3] J. Chan,et al. The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer , 2021, JAMA network open.
[4] C. Perou,et al. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer , 2021, Cancer Research.
[5] C. Sotiriou,et al. HER2-Low Breast Cancer: Molecular Characteristics and Prognosis , 2021, Cancers.
[6] J. Guan,et al. Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer , 2021, Cell reports.
[7] A. Lluch,et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer , 2021, NPJ breast cancer.
[8] H. Rugo,et al. Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] K. Hughes,et al. Disease Spectrum of Breast Cancer Susceptibility Genes , 2020, Frontiers in Oncology.
[10] F. Cardoso,et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Sapino,et al. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. , 2020, Seminars in cancer biology.
[12] C. Redfern,et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Perou,et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. D. de Vries,et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. , 2019, The Lancet. Oncology.
[15] C. Sotiriou,et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] N. Schultz,et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] B. Taylor,et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.
[18] A. Vincent-Salomon,et al. The Dilemma of HER2 Double-equivocal Breast Carcinomas , 2018, The American journal of surgical pathology.
[19] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.
[20] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Ville Mustonen,et al. The repertoire of mutational signatures in human cancer , 2018, Nature.
[22] Chunlei Liu,et al. ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..
[23] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[24] Quan Li,et al. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.
[25] Patrick Danaher,et al. Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.
[26] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[27] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[28] Renaud Gaujoux,et al. A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.
[29] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Kauraniemi,et al. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.
[31] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..